Vicore Pharma Holding Ab · OMXSTO:VICO
Vicore Pharma Holding Ab — Investor Presentation (November 2024)
30 slides from Vicore Pharma Holding Ab's investor presentation, November 2024
Slide 1: Vicore Pharma: Unlocking the potential of ATRAGs
VICORE PHARMA Unlocking the potential of a new class of drugs – Angiotensin II type 2 receptor agonists (ATRAGs) November 2024
Slide 2: Disclaimers
Disclaimers This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Vicore Pharma’s business, financial condition and
Slide 3: Vicore at a glance
Vicore at a glance Unlocking the potential of a new drug class – ATRAGs A powerful, upstream mechanism for idiopathic pulmonary fibrosis (IPF) Unprecedented FVC improvement and excellent safety profile in 36-week Phase 2a IPF trial Capitalizing on buloxibutid, while developing an ATRAG clinical prog
Slide 4: Company overview
Company overview Vision Transform the lives of patients where modulation of the AT2 (angiotensin II type 2) receptor can play a central role in halting and reversing disease pathology Locations Stockholm, Sweden, Cambridge, Massachusetts & Copenhagen, Denmark Financials Publicly listed (Nasdaq Stock
Slide 5: Advancing a diversified pipeline
Advancing a diversified pipeline Molecular Therapies Compound Indication Preclinical Phase 1 Phase 2 Phase 3 Comments Rights Global ex-Japan rights Buloxibutid Phase 2b ongoing IPF Japan: (C21) (NCT06588686) Multiple New ATRAGs Preclinical studies Fully-owned Indications Digital Therapies Compound I
Slide 6: IPF: A large and growing commercial opportunity
IPF: A large and growing commercial opportunity Large commercial market despite SoC shortcomings Majority of the market is not adequately addressed $6.2B+ Population in US and Europe Healthy lung Lung with $4.6B fibrosis ~250,000 $2.0B Only ~26% of US patients High discontinuation rate and initiate
Slide 7: Buloxibutid is a first-in-class AT2 receptor agonist
Buloxibutid is a first-in-class AT2 receptor agonist with the potential to transform the IPF landscape Phase 2b ASPIRE: confirming the Upstream MoA Exceptional clinical data clinical activity in a randomized, with strong preclinical data in the Phase 2a AIR trial placebo-controlled trial AT2 recepto
Slide 8: AT2R agonism is an upstream intervention driving tissue repair
AT2R agonism is an upstream intervention driving tissue repair • The angiotensin II pathway is highly conserved with similar components across species • Angiotensin II activates AT1R and AT2R • AT1R is widely expressed, while AT2R is consistently expressed in the lung, primarily on alveolar epitheli
Slide 9: AT2R is highly expressed in human lungs and on precursor AEC2s
AT2R is highly expressed in human lungs and specifically on precursor AEC2s AT2R—but not AT1R—is expressed in the human lung1 AT2R is selectively expressed on AEC2s2 (AT1R blocker) + buloxibutid Single cell analysis shows AT2 AT2R expression receptor selectively on AEC2 in the lung buloxibutid AEC2
Slide 10: Alveolar epithelial cells are critical for healthy lung function
Alveolar epithelial cells are critical for healthy lung function Healthy alveolus • The alveolar epithelium is constantly exposed to damaging irritants in inhaled air AEC2 • AEC1 is the predominant alveolar cell type and is responsible for gas exchange Proliferation • AEC2 is a progenitor cell that
Slide 11: Buloxibutid is an oral, selective AT2R agonist driving tissue repair
Buloxibutid is an oral, selective AT2R agonist that drives tissue repair via AEC2 precursor epithelial cells Alveolar compartment in IPF Effects of buloxibutid treatment Repeated Micro-injury Buloxibutid AEC2 dysfunction leads to reduced surfactant production, no generation Increased AEC2 viability
Slide 12: Buloxibutid protects AEC2s and drives increased surfactant production
Increased AEC2 viability & surfactant 1 production Buloxibutid protects AEC2s and drives increased surfactant production Surfactant protein expression increased by buloxibutid in Buloxibutid protects AEC2 cells against apoptosis1 ex vivo human IPF precision cut lung slices2 50 42% +120% % Increase v
Slide 13: Buloxibutid reduces TGFβ1 and collagen in human IPF lung slices
2 Inhibition of TGFβ1, EMT and collagen Buloxibutid reduces TGF1 and collagen in human IPF lung slices TGFβ1 protein levels in PCLuS Collagen protein levels in PCLuS Human precision cut lung slices (PCLuS) ✱✱ 150 4000 ✱ ✱✱ Collagen-1a1 (pg/mL) (pg/ml) (pg/mL) TGF11(pg/mL) 3000 100 Collagen-1a1 200
Slide 14: Buloxibutid downregulates expression of EMT transcription factors in AEC2
2 Inhibition of TGFβ1, EMT and collagen Buloxibutid downregulates expression of EMT transcription factors in AEC2 SNAIL1 SNAIL2 Vehicle 0.1µM 1µM Vehicle 0.1µM 1µM Vehicle 0.1µM 1µM Vehicle 0.1µM 1µM buloxibutid buloxibutid buloxibutid buloxibutid • Primary AEC2 cultures established from normal surg
Slide 15: MMP-13 demonstrates antifibrotic activity and is crucial for lung repair
3 Upregulation of collagenase MMPs MMP-13 demonstrates antifibrotic activity and is crucial for lung repair in IPF Collagenase MMP dysregulation contributes to IPF Buloxibutid increased plasma MMP-13 in the pathogenesis Phase 2a AIR trial • MMP-13 is an enzyme able to cleave fibrillar collagens 250
Slide 16: Strong preclinical in vivo evidence for buloxibutid in pulmonary fibrosis
Strong preclinical in vivo evidence for buloxibutid in pulmonary fibrosis Bleomycin Monocrotaline Sugen-Hypoxia 6 15 * * 7 ** ** * * * Hydroxy proline (nM) 6 Fibrosis (%) 4 10 Fibrosis (%) 5 2 5 4 0 0 3 Control BLEO buloxibutid C21 buloxibutid C21 Control MCT MCT MCT MCT + + C21 Control SuHx SuHx bu
Slide 17: AIR: Open-label Phase 2a trial of oral buloxibutid
AIR: An open-label Phase 2a trial of oral buloxibutid 100 mg BID for up to 36 weeks in treatment-naïve IPF patients Patient Patient population population Clinic visits with FVC measurements Treatment-naïve IPF Week 2 4 6 9 12 15 18 21 24 28 32 36 patients with Screening period Follow-up period centr
Slide 18: AIR baseline patient characteristics are in line with other IPF trials
AIR baseline patient characteristics are in line with other IPF trials Key Characteristics AIR INPULSIS 1&2 (N=52) (N=1,061)1 Age (years) - Mean (SD) 67 (9) 67 (8) Males 77% 80% In line with other trials. Gender Females 23% 20% White 27% 57% Enrolled study population has disease progression comparab
Slide 19: Treatment emergent adverse events: better tolerability than SoC
Treatment emergent adverse events: buloxibutid shows better tolerability than SoC INPULSIS 1 AIR 52-week treatment1 36-week treatment Nintedanib Placebo Buloxibutid n=309 n=204 n=52 Any AE 96% 89% 71% Common AEs (Non-exhaustive) Diarrhea 62% 19% 6% Good GI tolerability Nausea 23% 6% 4% Acute exacerb
Slide 20: Buloxibutid stabilizes and improves lung function over the AIR study
Buloxibutid stabilizes and improves lung function over the 36-week AIR study 400 *** 300 ** *** Buloxibutid FVC change (mL) 200 28 ** mean +SEM 28 28 100 * 33 40 34 0 32 n=48 44 35 34 48 39 -100 Untreated patients1,2 -200 0 4 8 12 16 20 24 28 32 36 Week 1Noble et al. Eur Respir J. 2016 Jan; 47(1): 2
Slide 21: All subgroups show FVC stabilization and improvement at 36 weeks
All subgroups show FVC stabilization and improvement over baseline at 36 weeks 400 Change at week 36 vs baseline Mean FVC change at week 36 vs baseline Mean and median; ∆mL Subgroup (# patients); ∆mL Mean FVC change at +216 ml week 36 vs baseline (all) Probable UIP (n=18); 321 300 Median FVC change
Slide 22: Buloxibutid drives a significant increase in ppFVC
Buloxibutid drives a significant increase in ppFVC, consistent with its impact on absolute FVC Average ppFVC change from baseline at week 36 8 7.5% Buloxibutid also demonstrated a 6 median FVC change from baseline at week 36 of +2.2% 4 2 % 0 -2 -2.0% -4 Nintedanib2 -4.2% -6 Buloxibutid1 Untreated2 A
Slide 23: Buloxibutid increases MMP-13 and drives a trend of decreased TGFβ1
Buloxibutid increases collagenase MMP-13 drives a trend of decreased TGFβ1 Plasma TGFβ1 Plasma MMP-13 20 250 ** 16 200 *** Plasma MMP-13 (% of baseline) Plasma TGFβ1 ** (ng/mL) 12 150 8 100 4 50 0 0 Baseline Week 12 Week 24 Week 36 Baseline Week 12 Week 24 Week 36 n=37 n=36 n=28 n=23 n=37 n=36 n=28
Slide 24: Phase 2b ASPIRE trial design
Phase 2b ASPIRE trial design A randomized, double-blind, placebo-controlled, parallel-group, multicenter, dose-finding trial IPF patients on stable nintedanib/SoC or not on SoC (no access, refused, intolerant or failed) 52-week treatment duration; N=270 (90 per arm) Study Assessment of efficacy, sa
Slide 25: Partnership with Nippon Shinyaku for buloxibutid in Japan
Vicore’s partnership with Nippon Shinyaku for buloxibutid in Japan Partnership Overview Vicore Pharma and Nippon Shinyaku have entered an exclusive license agreement to develop and commercialize the drug candidate buloxibutid in Japan. Financial Terms Vicore has received an upfront payment of USD 10
Slide 26: Almee is a digital therapy for anxiety in pulmonary fibrosis
Almee is a digital therapy for anxiety in pulmonary fibrosis with the potential to increase commercial sales of molecular therapies Product AlmeeTM is a digital companion to personalize pulmonary fibrosis treatment. description COMPANION study demonstrated clinical validation. Clinically Behavior mo
Slide 27: Almee provides multiple benefits for molecular assets
Almee provides multiple benefits for molecular assets Treats the psychological impact of living with PF Designed to improve QoL for patients which current SoCs don't address True patient engagement – designed to create trust and empowerment Increased Label & IP adherence, initiation, Data access Dif
Slide 28: Vicore has a platform of proprietary ATRAGs
Vicore has a platform of proprietary ATRAGs Buloxibutid – a first-in-class drug for rare lung diseases • Orphan drug status in IPF granted – Market exclusivity for 7 years in the US and 10 years in the EU. • Vicore has formulation and method-of-use IP granted in the US and EU covering buloxibutid, w
Slide 29: Strong leadership team with extensive industry experience
Strong leadership team with extensive industry experience AHMED MOUSA HANS JEPPSSON, PhD MIKAEL NYGÅRD, PhD CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER VP OPERATIONS AND CORPORATE STRATEGY Experienced biotech executive with a background in molecular Cross-disciplinary background in finance and m
Slide 30: Vicore is well positioned to unlock the potential of a new class of drugs
Vicore is well positioned to unlock the potential of a new class of drugs - in rare lung diseases and beyond Contact us Visiting addresses IR contacts www.vicorepharma.com Stockholm Copenhagen Boston AHMED MOUSA, CEO, ahmed.mousa@vicorepharma.com Kornhamnstorg 53 Agern Allé 5A One Broadway, 14th Flo
Vicore Pharma — Investor Presentation (November 2024) on 6ix